JP2023511337A5 - - Google Patents
Info
- Publication number
- JP2023511337A5 JP2023511337A5 JP2022543700A JP2022543700A JP2023511337A5 JP 2023511337 A5 JP2023511337 A5 JP 2023511337A5 JP 2022543700 A JP2022543700 A JP 2022543700A JP 2022543700 A JP2022543700 A JP 2022543700A JP 2023511337 A5 JP2023511337 A5 JP 2023511337A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituted
- optionally
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010056202.3 | 2020-01-19 | ||
| CN202010056202.3A CN113135910A (zh) | 2020-01-19 | 2020-01-19 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
| PCT/CN2021/071375 WO2021143701A1 (zh) | 2020-01-19 | 2021-01-13 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511337A JP2023511337A (ja) | 2023-03-17 |
| JP2023511337A5 true JP2023511337A5 (enExample) | 2024-01-22 |
| JP7716110B2 JP7716110B2 (ja) | 2025-07-31 |
Family
ID=76808550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543700A Active JP7716110B2 (ja) | 2020-01-19 | 2021-01-13 | ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230219946A1 (enExample) |
| EP (1) | EP4092024A4 (enExample) |
| JP (1) | JP7716110B2 (enExample) |
| KR (1) | KR102964789B1 (enExample) |
| CN (2) | CN113135910A (enExample) |
| AU (1) | AU2021208025B2 (enExample) |
| CA (1) | CA3168452A1 (enExample) |
| MX (1) | MX2022008881A (enExample) |
| WO (1) | WO2021143701A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CN116848121A (zh) * | 2020-12-18 | 2023-10-03 | 建新公司 | 制备shp2抑制剂的方法 |
| WO2022133217A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| TW202402761A (zh) * | 2022-03-28 | 2024-01-16 | 美商健臻公司 | 製備shp2抑制劑的方法 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117720550A (zh) * | 2023-12-14 | 2024-03-19 | 深圳市华先医药科技有限公司 | (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2824576T3 (es) * | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| KR102218333B1 (ko) * | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| WO2021043077A1 (zh) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
-
2020
- 2020-01-19 CN CN202010056202.3A patent/CN113135910A/zh active Pending
-
2021
- 2021-01-13 AU AU2021208025A patent/AU2021208025B2/en active Active
- 2021-01-13 JP JP2022543700A patent/JP7716110B2/ja active Active
- 2021-01-13 CN CN202180009655.3A patent/CN114981268B/zh active Active
- 2021-01-13 WO PCT/CN2021/071375 patent/WO2021143701A1/zh not_active Ceased
- 2021-01-13 EP EP21741216.2A patent/EP4092024A4/en active Pending
- 2021-01-13 US US17/793,571 patent/US20230219946A1/en active Pending
- 2021-01-13 MX MX2022008881A patent/MX2022008881A/es unknown
- 2021-01-13 CA CA3168452A patent/CA3168452A1/en active Pending
- 2021-01-13 KR KR1020227028172A patent/KR102964789B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102820455B1 (ko) | Shp2 활성 억제용 화합물의 제조 방법 | |
| JP2023519815A (ja) | スピロ環含有キナゾリン化合物 | |
| IL268030B2 (en) | Bicyclics as allosteric shp2 inhibitors | |
| ES2243441T3 (es) | Derivados de imidazolio fundidos. | |
| JP2023508482A (ja) | スピロ環含有キナゾリン化合物 | |
| WO2021088938A1 (zh) | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 | |
| WO2022161480A1 (zh) | 取代双环并芳杂环胺类抑制剂及其制备方法和应用 | |
| CA2831935A1 (en) | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use | |
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| DK2615092T3 (en) | Heterocyclic AMINOBERBAMIN DERIVATIVES, PREPARATION METHOD AND USE THEREOF | |
| CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
| HUT77943A (hu) | 2,5-Dioxo-piperazin-származékok, eljárás előállításukra és alkalmazásuk, valamint közbenső termékei | |
| WO2014047393A9 (en) | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds | |
| CA2837042C (en) | A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | |
| WO2022166592A1 (zh) | 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用 | |
| JP2019521964A5 (enExample) | ||
| US10358447B2 (en) | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same | |
| RU2656485C2 (ru) | Дейтерированные соединения хиназолинона и содержащие их фармацевтические композиции | |
| HUE027375T2 (en) | Phenyl guanidine derivatives | |
| WO2023040810A1 (en) | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors | |
| JP2017071567A (ja) | 抗がん剤デリバリー分子 | |
| US10550084B2 (en) | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | |
| JPH06234753A (ja) | イソオキサゾール化合物およびその塩 | |
| EP2625168A1 (en) | Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides | |
| JP7184302B2 (ja) | ヒトトレフォイル因子３の阻害に有用な化合物 |